Loading
Oculis
Oculis Holding AG (Nasdaq: OCS; Nasdaq Iceland) develops late-stage, non-invasive topical treatments for front- and back-of-the-eye diseases. Its candidates include OCS-01 for diabetic macular edema and licaminlimab (OCS-02) for dry eye. It is pre-commercial and funds R&D through venture and public-market capital, with about $192M raised across four rounds per Datanyze. It was founded in Reykjavík, Iceland, and is now headquartered in Zug, Switzerland. In August 2026 it signed an asset purchase agreement for privosegtor to build out its neuro-ophthalmology pipeline.
Funding
Every round, secondary, debt facility or acquisition involving Oculis that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—